Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

Conclusion The RD was determined to be 50 mg/m2/day of TAS-102 combined with 150 mg/m2 of irinotecan although further investigation to explore optimal regimen is warranted.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research